Abstract 287MO
Background
Real world Indian data with maintenance Poly ADP Ribose Polymerase 1 Inhibitors (PARPi) in newly diagnosed advanced ovarian cancer (AOC) are lacking. The purpose of this study was to evaluate optimal dosing, safety and efficacy of olaparib or rucaparib maintenance plus minus bevacizumab in germline BRCA mutations or HRD-positive AOC patients.
Methods
This was a retrospective study from Tata Medical Center, Kolkata, West Bengal, India; included patients with stage III & IV (AJCC 7th) AOC between 2020- 2023. All data captured from electronic medical records of hospital up till June 2023. Either standard dose or reduced dose of tablet olaparib (450mg/day orally) or rucaparib (600mg/day orally) plus minus injection bevacizumab (7.5 mg/kg IV q 3weekly) was offered as a front-line maintenance therapy after completion of surgery and platinum based chemotherapy without any residual disease.
Results
Out of 89 screened patients, 41 received therapy with a median age at diagnosis 57 years (range 41-74). 98% had high grade serous histology with 61% stage III and 39% stage IV diseases. 28(68%) patients had germline BRCA mutations and 13(32%) HRD-positive (high genomic scar score). 34(82%) patients received maintenance bevacizumab up to one year along with PARPi. The duration of exposure of PARPi ranged from 2-24 months and 63% patients started with reduced dose. Dose reductions due to adverse effects (AEs) seen in 42%. With a median follow up of 32 months (95% CI 22.04-41.95); two years predicted progression free survival (PFS) of the entire cohort was 84%, no difference in PFS between standard dose and reduced dose group (30 vs 35 months; log rank p=0.67). There was no significant difference in PFS among olaparib and rucaparib (NR vs 35 months; log rank p=0.20). The most common ≥ grade III AEs (CTCAE V.5) were anemia (24%), thrombocytopenia (7%), fatigue (22%), diarrhea (2%) and transamnitis (5%).
Conclusions
We found that lower doses of PARPi were equally efficacious with good tolerance in comparison with standard dose and can be offered as first-line maintenance therapy in AOC patients with germline BRCA mutation or HRD positive in a resource-limited setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
285O - Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study
Presenter: Svetlana Khokhlova
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
286MO - Efficacy of low dose nivolumab in recurrent / metastatic cervical cancer
Presenter: Sowmica Devabhaktuni
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 285O, 286MO and 287MO
Presenter: Smruti Koppikar
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
288MO - InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
289MO - Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study
Presenter: Xiaotian Han
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
290MO - Efficacy and safety of topical sintilimab administration in conjunction with CRT and Californium-252 neutron brachytherapy in first-line advanced gynecological squamous cell carcinoma patients
Presenter: Xiaoling Li
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 288MO, 289MO and 290MO
Presenter: Alexandra Leary
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
LBA8 - Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast